The US Foods and Drug Administration(FDA) on Monday approved Biogen's aducanumab drug for Alzheimer's patience.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s. On behalf of those impacted by Alzheimer’s &amp; all other dementia, we celebrate today’s historic decision. <a href="https://t.co/2oJIeMADog">pic.twitter.com/2oJIeMADog</a>
— Alzheimer's Association (@alzassociation) <a href="https://twitter.com/alzassociation/status/1401922061816287236?ref_src=twsrc%5Etfw">June 7, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The FDA said: "There is substantial evidence that aducanumab reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients."

However, the US drug regulator did say that "aducanumab data" is "complicated" with respect to its clinical benefits.

During Alzheimer's a patient suffers from memory loss and is unable to take care of himself, the drug reportedly aims to remove amyloid beta from the brains of patients in the early stages of the disease.

However, the FDA asserted that if the drug does not work it could remove it. The regulator has given&nbsp;"Accelerated Approval" to the drug since it believes it benefits patients over existing treatments but there is still some uncertainty.

The FDA hasn't approved a single Alzheimer’s drug since 2003.

The drug however has produced mixed results. In 2019, the company had halted trials after a committee said the drug didn't show any results, however, the company last year said that it worked when a patient was given a higher dose.

"As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives," FDA's Patrizia Cavazzoni said.

Other companies including Pfizer and Johnson &amp; Johnson had earlier scrapped their study including Merck whose trials failed four years ago. Eli Lilly and Roche also failed to make an impact with their drugs.

There are reportedly 6 million people in the US who suffer from Alzheimer's.

(With inputs from Agencies)

The US Foods and Drug Administration(FDA) on Monday approved Biogen's aducanumab drug for Alzheimer's patience. Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s.

The US Foods and Drug Administration(FDA) on Monday approved Biogen's aducanumab drug for Alzheimer's patience. Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s. On behalf of those impacted by Alzheimer’s & all other dementia, we celebrate today’s historic decision. pic.twitter.com/2oJIeMADog — Alzheimer's Association (@alzassociation) June 7, 2021 × The FDA said: "There is substantial evidence that aducanumab reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients." However, the US drug regulator did say that "aducanumab data" is "complicated" with respect to its clinical benefits. During Alzheimer's a patient suffers from memory loss and is unable to take care of himself, the drug reportedly aims to remove amyloid beta from the brains of patients in the early stages of the disease. However, the FDA asserted that if the drug does not work it could remove it. The regulator has given "Accelerated Approval" to the drug since it believes it benefits patients over existing treatments but there is still some uncertainty. The FDA hasn't approved a single Alzheimer’s drug since 2003. The drug however has produced mixed results. In 2019, the company had halted trials after a committee said the drug didn't show any results, however, the company last year said that it worked when a patient was given a higher dose. "As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives," FDA's Patrizia Cavazzoni said. Other companies including Pfizer and Johnson & Johnson had earlier scrapped their study including Merck whose trials failed four years ago. Eli Lilly and Roche also failed to make an impact with their drugs. There are reportedly 6 million people in the US who suffer from Alzheimer's. (With inputs from Agencies)

In major breakthrough, US FDA approves new Alzheimer's drug

A trial drug has shown encouraging signs of there being an effective treatment for Alzheimer&#39;s disease. 
 
The drug, named&nbsp;aducanumab, is an antibody that showed &quot;almost complete clearance&quot; of sticky proteins that clot in the brain, a reason that is believed to cause Alzheimer&#39;s. The sticky proteins are known as&nbsp;Amyloids. 
 
Experts, however, moved quickly to downplay the significance of the experiment.&nbsp; 
 
Robert Howard, a professor of old age psychiatry at University College London, told AFP,&nbsp;&quot;Although potentially this is an exciting story, it is important to temper any excitement with considerable caution.&quot; 
 
Incidentally,&nbsp;aducanumab is not the first antibody to show positive signs in Phase I&nbsp;of the drug trial. The Phase III efficacy test is the crucial period for any experimental drug.&nbsp; 
 
&quot;It would be premature to conclude that this is likely to represent an effective treatment for Alzheimer&#39;s disease,&quot; professor Howard said.&nbsp; 
 
Aducanumab, an antibody developed by biotech firm Biogen, was used on 165 people suffering from early-stage Alzheimer&#39;s for a year.&nbsp; 
 
The drug recorded&nbsp;some side-effects, including headaches. 
 
Nearly 44 million people have Alzheimer&#39;s disease or a related dementia across the world. 
 
In the US, Alzheimer&#39;s is the sixth-leading cause of death.&nbsp;&nbsp; 
 
According to World Health Organisation (WHO), around 7.7 million people are diagnosed with the disease every year.&nbsp; 
 
At the moment, there is no effective treatment for&nbsp;Alzheimer&#39;s disease, which leads to memory loss in old age. 
 
(WION with inputs from AFP)

The antibody showed 'almost complete clearance' of sticky proteins that clot in the brain, a reason that is believed to cause the disease

A trial drug has shown encouraging signs of there being an effective treatment for Alzheimer's disease. The drug, named aducanumab, is an antibody that showed "almost complete clearance" of sticky proteins that clot in the brain, a reason that is believed to cause Alzheimer's. The sticky proteins are known as Amyloids. Experts, however, moved quickly to downplay the significance of the experiment. Robert Howard, a professor of old age psychiatry at University College London, told AFP, "Although potentially this is an exciting story, it is important to temper any excitement with considerable caution." Incidentally, aducanumab is not the first antibody to show positive signs in Phase I of the drug trial. The Phase III efficacy test is the crucial period for any experimental drug. "It would be premature to conclude that this is likely to represent an effective treatment for Alzheimer's disease," professor Howard said. Aducanumab, an antibody developed by biotech firm Biogen, was used on 165 people suffering from early-stage Alzheimer's for a year. The drug recorded some side-effects, including headaches. Nearly 44 million people have Alzheimer's disease or a related dementia across the world. In the US, Alzheimer's is the sixth-leading cause of death. According to World Health Organisation (WHO), around 7.7 million people are diagnosed with the disease every year. At the moment, there is no effective treatment for Alzheimer's disease, which leads to memory loss in old age. (WION with inputs from AFP)

Trial drug kindles hopes of Alzheimer's treatment

aducanumab

Aducanumab, News on Aducanumab, stories on Aducanumab, articles on Aducanumab, Aducanumab stories at Wion, Aducanumab news, Aducanumab latest news